-
Product Insights
Hypoxia - Drugs In Development, 2024
Empower your strategies with our Hypoxia – Drugs In Development, 2024 report and make more profitable business decisions. Hypoxia is a condition in which oxygen is not available in sufficient amounts at the tissue level to maintain adequate homeostasis; this can result from inadequate oxygen delivery to the tissues either due to low blood supply or low oxygen content in the blood (hypoxemia). Hypoxia can vary in intensity from mild to severe and can present in acute or chronic form. The...
-
Product Insights
Primary Ciliary Dyskinesia - Drugs In Development, 2024
Empower your strategies with our Primary Ciliary Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Primary ciliary dyskinesia, or PCD, is a rare disease that affects the tiny, hairlike structures (cilia) that line the airways. PCD affects mainly the sinuses, ears, and lungs. Some people who have PCD have breathing problems from birth. The symptoms and severity of PCD vary from person to person. Symptoms may be mild at first and worsen over time. The Primary...
-
Product Insights
Respiratory Failure - Drugs In Development, 2024
Empower your strategies with our Respiratory Failure – Drugs In Development, 2024 report and make more profitable business decisions. The respiratory system allows gas exchange between the environment and the body, facilitating the process of aerobic metabolism. Specifically, the respiratory system provides oxygen and removes carbon dioxide from the body. The inability of the respiratory system to perform either or both of these tasks results in respiratory failure. Respiratory failure can be classified based on chronicity: acute, chronic, and acute on...
-
Product Insights
Neonatal Respiratory Distress Syndrome - Drugs In Development, 2024
Empower your strategies with our Neonatal Respiratory Distress Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Neonatal respiratory distress syndrome, or RDS, is a common cause of respiratory distress in a newborn, presenting within hours after birth, most often immediately after delivery. It usually affects preterm neonates and term infants. The incidence of RDS is inversely proportional to the gestational age of the infant, with more severe disease in the smaller and more premature neonates. Treatment...
-
Product Insights
Chronic Bronchitis - Drugs In Development, 2024
Empower your strategies with our Chronic Bronchitis – Drugs In Development, 2024 report and make more profitable business decisions. Chronic Bronchitis is a type of chronic obstructive pulmonary disease (COPD) that refers to long-term inflammation of the bronchi. This is a productive cough of more than 3 months occurring within a span of 2 years. The Chronic Bronchitis drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Bronchitis, complete with analysis by stage of...
-
Product Insights
Hospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hospital Acquired Pneumonia (HAP) Clinical Trial Report Overview A total of 581 HAP clinical trials were conducted as of April 2024. The HAP clinical trial report provides a comprehensive understanding of the HAP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe...
-
Product Insights
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial Report Overview The total number of chronic obstructive pulmonary disease (COPD) clinical trials conducted as of December 2023 was 3,584. The COPD clinical trial report includes information about the sponsor type and the prominent sponsors associated with the COPD clinical trials. The report provides a comprehensive understanding of the COPD clinical trial scenario across regions and countries (G7 & E7), covering details on the various phases, trial status, and end points status. The...
-
Product Insights
Ventilator Associated Pneumonia (VAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ventilator Associated Pneumonia (VAP) Clinical Trials Market Report Overview The Ventilator Associated Pneumonia (VAP) clinical trial market research report provides an overview of Ventilator Associated Pneumonia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Ventilator Associated Pneumonia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Thematic Analysis
Digital Marketing Trends in Severe Asthma
Digital Marketing Trends in Asthma Report Overview Sanofi/Regeneron’s Dupixent.com achieved the highest total traffic across branded asthma patient sites in the US and branded asthma HCP sites in the US from June 2022 to May 2023. In addition, there were a few unbranded asthma sites detected in the US. Amgen/AstraZeneca’s Breakthecycle.com had the highest level of traffic from June 2022 to May 2023 with more than 180,000 visits. Between June 2022 and May 2023, over 200 social media posts related...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.